About this Journal Submit a Manuscript Table of Contents
Mediators of Inflammation
Volume 2013 (2013), Article ID 413826, 8 pages
http://dx.doi.org/10.1155/2013/413826
Research Article

Regulation and Prognostic Relevance of Symmetric Dimethylarginine Serum Concentrations in Critical Illness and Sepsis

1Department of Medicine III, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany
2Institute of Clinical Chemistry and Pathobiochemistry, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

Received 23 April 2013; Revised 3 June 2013; Accepted 10 June 2013

Academic Editor: Jesús F. Bermejo-Martin

Copyright © 2013 Alexander Koch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. De Backer, J. Creteur, J.-C. Preiser, M.-J. Dubois, and J.-L. Vincent, “Microvascular blood flow is altered in patients with sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 1, pp. 98–104, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. D. De Backer, K. Donadello, Y. Sakr et al., “Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome,” Critical Care Medicine, vol. 41, pp. 791–799, 2013.
  3. A. Donati, R. Domizi, E. Damiani, E. Adrario, P. Pelaia, and C. Ince, “From macrohemodynamic to the microcirculation,” Critical Care Research and Practice, vol. 2013, Article ID 892710, 8 pages, 2013. View at Publisher · View at Google Scholar
  4. G. Hernandez, A. Bruhn, and C. Ince, “Microcirculation in sepsis: new perspectives,” Current Vascular Pharmacology, vol. 11, pp. 161–169, 2013.
  5. S. Skibsted, A. E. Jones, M. A. Puskarich et al., “Biomarkers of endothelial cell activation in early sepsis,” Shock, vol. 39, pp. 427–432, 2013.
  6. D. W. Landry and J. A. Oliver, “The pathogenesis of vasodilatory shock,” New England Journal of Medicine, vol. 345, no. 8, pp. 588–595, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Davis, C. J. Darcy, T. W. Yeo et al., “Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis,” PLoS ONE, vol. 6, no. 2, Article ID e17260, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Iapichino, M. Umbrello, M. Albicini et al., “Time course of endogenous nitric oxide inhibitors in severe sepsis in humans,” Minerva Anestesiologica, vol. 76, no. 5, pp. 325–333, 2010. View at Scopus
  9. R. J. Nijveldt, T. Teerlink, B. Van Der Hoven et al., “Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality,” Clinical Nutrition, vol. 22, no. 1, pp. 23–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. O'Dwyer, F. Dempsey, V. Crowley, D. P. Kelleher, R. McManus, and T. Ryan, “Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study,” Critical Care, vol. 10, no. 5, article R139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Koch, R. Weiskirchen, and J. Kunze, “Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patients,” Journal of Critical Care. In press. View at Publisher · View at Google Scholar
  12. A. A. Mangoni, “Chapter 3 the emerging role of symmetric dimethylarginine in vascular disease,” Advances in Clinical Chemistry, vol. 48, pp. 73–94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Leiper and P. Vallance, “Biological significance of endogenous methylarginines that inhibit nitric oxide synthases,” Cardiovascular Research, vol. 43, no. 3, pp. 542–548, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Schwedhelm and R. H. Böger, “The role of asymmetric and symmetric dimethylarginines in renal disease,” Nature Reviews Nephrology, vol. 7, no. 5, pp. 275–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. M. Bode-Böger, F. Scalera, J. T. Kielstein et al., “Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease,” Journal of the American Society of Nephrology, vol. 17, no. 4, pp. 1128–1134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Koch, O. A. Gressner, E. Sanson, F. Tacke, and C. Trautwein, “Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients,” Critical Care, vol. 13, no. 3, article R95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Koch, E. Sanson, A. Helm, S. Voigt, C. Trautwein, and F. Tacke, “Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis,” Critical Care, vol. 14, no. 3, article R94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Koch, R. Weiskirchen, H. W. Zimmermann, E. Sanson, C. Trautwein, and F. Tacke, “Relevance of serum leptin and leptin-receptor concentrations in critically ill patients,” Mediators of Inflammation, vol. 2010, Article ID 473540, 9 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Koch, S. Voigt, C. Kruschinski et al., “Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients,” Critical Care, vol. 15, no. 1, article R63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Backes, K. F. van der Sluijs, D. P. Mackie et al., “Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review,” Intensive Care Medicine, vol. 38, pp. 1418–1428, 2012.
  21. R. H. Böger, “Live and let die: asymmetric dimethylarginine and septic shock,” Critical Care, vol. 10, no. 6, article 169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. T. Kielstein, R. H. Böger, S. M. Bode-Böger et al., “Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease,” Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 594–600, 1999. View at Scopus
  23. T. Ogawa, M. Kimoto, H. Watanabe, and K. Sasaoka, “Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats,” Archives of Biochemistry and Biophysics, vol. 252, no. 2, pp. 526–537, 1987. View at Scopus
  24. S. Kiechl, T. Lee, P. Santer et al., “Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population,” Atherosclerosis, vol. 205, no. 1, pp. 261–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Leiper, M. Nandi, B. Torondel et al., “Disruption of methylarginine metabolism impairs vascular homeostasis,” Nature Medicine, vol. 13, no. 2, pp. 198–203, 2007. View at Publisher · View at Google Scholar · View at Scopus